Generic placeholder image

Current Respiratory Medicine Reviews

Author(s): Mukesh Masand*, Pramod Kumar Sharma, Vishal M. Balaramnavar and Deepti Mathpal

DOI: 10.2174/1573398X18666220503184459

DownloadDownload PDF Flyer Cite As
Tuberculosis: Current Progress in Drug Targets, Potential Drugs and Therapeutic Impact

Page: [165 - 170] Pages: 6

  • * (Excluding Mailing and Handling)

Explore Articles
About Journal
For Authors
For Editors
For Reviewers

Abstract

The World Health Organization (WHO) considers tuberculosis to be the most dangerous chronic communicable disease in the world, infecting two billion people or one-third of the world’s population. Tuberculosis (TB) caused by Mycobacterium tuberculosis remains a leading cause of mortality worldwide into the 21st century. Tuberculosis is second only to AIDS among other infectious diseases causing deaths worldwide. The emergence of AIDS, multidrug-resistant TB (MDRTB), extensively drug-resistant tuberculosis (XDR-TB), the decline of socioeconomic standards, and a reduced emphasis on tuberculosis control programmers contribute to the disease’s resurgence in industrialized countries.

Keywords: Phthisis, white plague, drug resistance, multidrug-resistant TB (MDR-TB), extensively drug-resistant tuberculosis (XDR-TB), fluoroquinolones (FQ), topoisomerases, phototoxicity.

[1]
Cave AJE, Demonstrator A. The evidence for the incidence of the tuberculosis in ancient Egypt. British J Tuberculosis 1939; 33(3): 142-52.
[http://dx.doi.org/10.1016/S0366-0850(39)80016-3]
[2]
Daniel TM. The history of tuberculosis. Respir Med 2006; 100(11): 1862-70.
[http://dx.doi.org/10.1016/j.rmed.2006.08.006] [PMID: 16949809]
[3]
Kwan CK, Ernst JD. HIV and tuberculosis: a deadly human syndemic. Clin Microbiol Rev 2011; 24(2): 351-76.
[http://dx.doi.org/10.1128/CMR.00042-10] [PMID: 21482729]
[4]
World Health Organization. Global Tuberculosis control report. 2020. Available from: https://www.who.int/publications/i/item/9789240013131
[5]
Sharma SK, Mohan A. Multidrug-resistance tuberculosis. Chest 2006; 130(1): 261-72.
[http://dx.doi.org/10.1016/S0012-3692(15)50981-1] [PMID: 16840411]
[6]
World Health Organization. Available from: https://www. who.int/tb/areas-of-work/drug-resistant-tb/MDR_TB_2017.pdf
[7]
Girling DJ. The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle 1978; 59(1): 13-32.
[http://dx.doi.org/10.1016/0041-3879(77)90022-8] [PMID: 345572]
[8]
Azhar GS. DOTS for TB relapse in India: A systematic review. Lung India 2012; 29(2): 147-53.
[http://dx.doi.org/10.4103/0970-2113.95320] [PMID: 22628930]
[9]
WHO treatment guidelines for drug-resistant tuberculosis 2016 update WHO/HTM/TB 201604 Geneva. World Health Organization 2016.
[10]
Appelbaum PC, Hunter PA. The fluoroquinolone antibacterials: past, present and future perspectives. Int J Antimicrob Agents 2000; 16(1): 5-15.
[http://dx.doi.org/10.1016/S0924-8579(00)00192-8] [PMID: 11185413]
[11]
Di Perri G, Bonora S. Which agents should we use for the treatment of multidrug-resistant Mycobacterium tuberculosis? J Antimicrob Chemother 2004; 54(3): 593-602.
[http://dx.doi.org/10.1093/jac/dkh377] [PMID: 15282233]
[12]
Rubinstein E. History of quinolones and their side effects. Chemotherapy 2001; 47(Suppl. 3): 3-8.
[http://dx.doi.org/10.1159/000057838] [PMID: 11549783]
[13]
Aldred KJ, Kerns RJ, Osheroff N. Mechanism of quinolone action and resistance. Biochemistry 2014; 53(10): 1565-74.
[http://dx.doi.org/10.1021/bi5000564] [PMID: 24576155]
[14]
Gawad J, Bonde C. Current affairs, future perspectives of tuberculosis and antitubercular agents. Indian J Tuberc 2018; 65(1): 15-22.
[http://dx.doi.org/10.1016/j.ijtb.2017.08.011] [PMID: 29332642]
[15]
Jia L, Tomaszewski JE, Hanrahan C, et al. Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. Br J Pharmacol 2005; 144(1): 80-7.
[http://dx.doi.org/10.1038/sj.bjp.0705984] [PMID: 15644871]
[16]
Lee RE, Protopopova M, Crooks E, Slayden RA, Terrot M, Barry CE III. Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates. J Comb Chem 2003; 5(2): 172-87.
[http://dx.doi.org/10.1021/cc020071p] [PMID: 12625709]
[17]
Jia L, Tomaszewski JE, Noker PE, Gorman GS, Glaze E, Protopopova M. Simultaneous estimation of pharmacokinetic properties in mice of three anti-tubercular ethambutol analogs obtained from combinatorial lead optimization. J Pharm Biomed Anal 2005; 37(4): 793-9.
[http://dx.doi.org/10.1016/j.jpba.2004.11.036] [PMID: 15797803]
[18]
Lenaerts AJ, Gruppo V, Marietta KS, et al. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuber-culosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother 2005; 49(6): 2294-301.
[http://dx.doi.org/10.1128/AAC.49.6.2294-2301.2005] [PMID: 15917524]
[19]
Stover CK, Warrener P, VanDevanter DR, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000; 405(6789): 962-6.
[http://dx.doi.org/10.1038/35016103] [PMID: 10879539]
[20]
Lewis JM, Sloan DJ. The role of delamanid in the treatment of drug-resistant tuberculosis. Ther Clin Risk Manag 2015; 11: 779-91.
[PMID: 25999726]
[21]
Shimokawa Y, Sasahara K, Koyama N, et al. Metabolic mechanism of delamanid, a new anti-tuberculosis drug, in human plasma. Drug Metab Dispos 2015; 43(8): 1277-83.
[http://dx.doi.org/10.1124/dmd.115.064550] [PMID: 26055621]
[22]
Sasahara K, Shimokawa Y, Hirao Y, et al. Pharmacokinetics and metabolism of delamanid, a novel anti-tuberculosis drug, in animals and humans: Importance of albumin metabolism in vivo. Drug Metab Dispos 2015; 43(8): 1267-76.
[http://dx.doi.org/10.1124/dmd.115.064527] [PMID: 26055620]
[23]
Mallikaarjun S, Wells C, Petersen C, et al. Delamanid coadministered with antiretroviral drugs or antituberculosis drugs shows no clinical-ly relevant drug‐drug interactions in healthy subjects. Antimicrob Agents Chemother 2016; 60(10): 5976-85.
[http://dx.doi.org/10.1128/AAC.00509-16] [PMID: 27458223]
[24]
Lin AH, Murray RW, Vidmar TJ, Marotti KR. The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with bind-ing of chloramphenicol and lincomycin. Antimicrob Agents Chemother 1997; 41(10): 2127-31.
[http://dx.doi.org/10.1128/AAC.41.10.2127] [PMID: 9333036]
[25]
Cynamon MH, Klemens SP, Sharpe CA, Chase S. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother 1999; 43(5): 1189-91.
[http://dx.doi.org/10.1128/AAC.43.5.1189] [PMID: 10223934]
[26]
Douros A, Grabowski K, Stahlmann R. Drug-drug interactions and safety of linezolid, tedizolid, and other oxazolidinones. Expert Opin Drug Metab Toxicol 2015; 11(12): 1849-59.
[http://dx.doi.org/10.1517/17425255.2015.1098617] [PMID: 26457865]
[27]
Jadhavar PS, Vaja MD, Dhameliya TM, Chakraborti AK. Oxazolidinones as anti‐tubercular agents: discovery, development and future perspectives. Curr Med Chem 2015; 22(38): 4379-97.
[http://dx.doi.org/10.2174/0929867323666151106125759] [PMID: 26549430]
[28]
Thompson J, O’Connor M, Mills JA, Dahlberg AE. The protein synthesis inhibitors, oxazolidinones and chloramphenicol, cause exten-sive translational inaccuracy in vivo. J Mol Biol 2002; 322(2): 273-9.
[http://dx.doi.org/10.1016/S0022-2836(02)00784-2] [PMID: 12217690]
[29]
Kundu S, Biukovic G, Grüber G, Dick T. Bedaquiline targets the ε subunit of mycobacterial F‐ATP synthase. Antimicrob Agents Chemother 2016; 60(11): 6977-9.
[http://dx.doi.org/10.1128/AAC.01291-16] [PMID: 27620476]
[30]
Wolfson LJ, Walker A, Hettle R, et al. Cost-effectiveness of adding bedaquiline to drug regimens for the treatment of multidrug-resistant tuberculosis in the UK. PLoS One 2015; 10(3): e0120763.
[http://dx.doi.org/10.1371/journal.pone.0120763] [PMID: 25794045]
[31]
Brecik M, Centárová I, Mukherjee R, et al. DprE1 is a vulnerable tuberculosis drug target due to its cell wall localization. ACS Chem Biol 2015; 10(7): 1631-6.
[http://dx.doi.org/10.1021/acschembio.5b00237] [PMID: 25906160]
[32]
Richter A, Rudolph I, Möllmann U, et al. Novel insight into the reaction of nitro, nitroso and hydroxylamino benzothiazinones and of benzoxacinones with Mycobacterium tuberculosis DprE1. Sci Rep 2018; 8(1): 13473.
[http://dx.doi.org/10.1038/s41598-018-31316-6] [PMID: 30194385]
[33]
Shirude PS, Shandil R, Sadler C, et al. Azaindoles: Noncovalent DprE1 inhibitors from scaffold morphing efforts, kill Mycobacterium tuberculosis and are efficacious in vivo. J Med Chem 2013; 56(23): 9701-8.
[http://dx.doi.org/10.1021/jm401382v] [PMID: 24215368]
[34]
Piton J, Foo CS, Cole ST. Structural studies of Mycobacterium tuberculosis DprE1 interacting with its inhibitors. Drug Discov Today 2017; 22(3): 526-33.
[http://dx.doi.org/10.1016/j.drudis.2016.09.014] [PMID: 27666194]
[35]
Wilsey C, Gurka J, Toth D, Franco J. A large scale virtual screen of DprE1. Comput Biol Chem 2013; 47: 121-5.
[http://dx.doi.org/10.1016/j.compbiolchem.2013.08.006] [PMID: 24055764]
[36]
Sarathy JP, Ganapathy US, Zimmerman MD, Dartois V, Gengenbacher M, Dick T. TBAJ-876, a 3,5-dialkoxypyridine analogue of bedaq-uiline, is active against mycobacterium abscessus. Antimicrob Agents Chemother 2020; 64(4): e02404-19.
[http://dx.doi.org/10.1128/AAC.02404-19] [PMID: 31964791]
[37]
Xu J, Converse PJ, Upton AM, Mdluli K, Fotouhi N, Nuermberger EL. Comparative efficacy of the novel diarylquinoline TBAJ-587 and bedaquiline against a resistant Rv0678 mutant in a mouse model of tuberculosis. Antimicrob Agents Chemother 2021; 65(4): e02418-20.
[http://dx.doi.org/10.1128/AAC.02418-20] [PMID: 33526488]
[38]
Foti C, Piperno A, Scala A, Giuffrè O. Oxazolidinone antibiotics: chemical, biological and analytical aspects. Molecules 2021; 26(14): 4280.
[http://dx.doi.org/10.3390/molecules26144280] [PMID: 34299555]
[39]
Zhang Y, Zhu H, Fu L, et al. Identifying regimens containing TBI-166, a new drug candidate against mycobacterium tuberculosis in vitro and in vivo. Antimicrob Agents Chemother 2019; 63(7): e02496-18.
[http://dx.doi.org/10.1128/AAC.02496-18] [PMID: 31061157]
[40]
Xu J, Wang B, Fu L, et al. In vitro and in vivo Activities of the Riminophenazine TBI-166 against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2019; 63(5): e02155-18.
[http://dx.doi.org/10.1128/AAC.02155-18] [PMID: 30782992]
[41]
de Jager VR, Dawson R, van Niekerk C, et al. Telacebec (Q203), a new antituberculosis agent. N Engl J Med 2020; 382(13): 1280-1.
[http://dx.doi.org/10.1056/NEJMc1913327] [PMID: 32212527]
[42]
Stokes SS, Vemula R, Pucci MJ. Advancement of GyrB inhibitors for treatment of infections caused by mycobacterium tuberculosis and non-tuberculous mycobacteria. ACS Infect Dis 2020; 6(6): 1323-31.
[http://dx.doi.org/10.1021/acsinfecdis.0c00025] [PMID: 32183511]
[43]
Pennings LJ, Ruth MM, Wertheim HFL, van Ingen J. The benzimidazole SPR719 shows promising concentration-dependent activity and synergy against nontuberculous mycobacteria. Antimicrob Agents Chemother 2021; 65(4): e02469-20.
[http://dx.doi.org/10.1128/AAC.02469-20] [PMID: 33468478]